Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: $Mogul who wrote (92450)	8/31/1999 3:47:00 PM
From: Caravan	Read Replies (1) \| Respond to of 119973

KING, Look for big gapper on this one when the news hits the networks tonight. Tuesday August 31, 7:37 am Eastern Time Heart drug could save million lives a year --study LONDON, Aug 31 (Reuters) - A drug currently being used to treat heart failure and high blood pressure could also prevent heart attacks and strokes in high-risk patients and save up to a million lives a year, doctors said on Tuesday. Researchers who presented the results of an international trial of ramipril at a medical conference in Barcelona said the drug reduced the risk of heart attacks and strokes in high-risk patients by between 20 and 30 percent. ``If ramipril is widely used in high-risk patients, nearly one million unnecessary deaths, heart attacks and strokes could be prevented each year,' Dr Salim Yusuf of Canada's McMacster University, the chairman of the HOPE Study, said in a statement released in London. Coronary heart disease, the leading cause of death in the Western world, kills about six million people each year. Doctors who tested ramipril, a so-called ACE inhibitor, on 9,500 patients in 19 countries were so impressed by the results that they stopped the five-year trial six months early. Ramipril is marketed by Hoechst Marion Roussel (quote from Yahoo! UK & Ireland: HOEG.F), and in the United States by King Pharmaceuticals Inc (Nasdaq:KING - news). ``We have an enormous problem across the world with coronary heart disease and stroke. Those pathologies account for virtually 50 percent of all deaths in this country,' said Dr John Kennedy, of Glasgow's Western Infirmary, who led the study in Britain. People who survive a heart attack or stroke have an increased risk of having another attack. Doctors think ramipril can prevent future problems in these patients. ``At the time of discharge from hospital we would anticipate now that they would in future be prescribed ramipril on the basis of evidence accrued from this study,' Kennedy added. ACE (angiotensin converting enzyme) inhibitors are a class of drugs that are used to lower high blood pressure. The drugs work by preventing angiotensin I, a harmless peptide, from converting into angiotensin II, which causes blood vessels to constrict and increases blood pressure. All of the patients who took part in the study were 55 or older and had suffered previous cardiovascular conditions such as a heart attack or stroke, or had other risk factors such as diabetes or smoking which made them more susceptible to further problems. Ramipril not only prevented subsequent heart attacks and strokes but also reduced the need for heart bypasses and other types of surgery and hospital stays. Patients who took the drug over several years also reported fewer side effects. Hoechst Marion Roussel said it would apply for a licence for the drug to be used as a preventive measure based on the results of the study. The findings of the HOPE (Heart Outcomes Prevention Evaluation) Study were presented at a cardiology conference in Barcelona.

To: $Mogul who wrote (92450)	8/31/1999 3:49:00 PM
From: flyboy	Respond to of 119973

Market reversal... Headed lower now!

To: $Mogul who wrote (92450)	8/31/1999 3:49:00 PM
From: hotlinktuna	Read Replies (1) \| Respond to of 119973

Jason...the BRNC I rec'd at 9 3/8 last week is "HOT" again!! From 9 13/16 low this morning to 11 at the high of the day now! Looking for a nice gap in a.m. if market holds up next 10 minutes and I think it will. tuna

To: $Mogul who wrote (92450)	8/31/1999 4:41:00 PM
From: 2MAR$	Respond to of 119973

IIJI...AUG 31, 1999, M2 Communications - Internet Initiative Japan Inc., (IIJ) (headquarters: Chiyoda-ku, Tokyo; president: Koichi Suzuki; NASDAQ symbol IIJI), will launch a new service, IIJ T1 Standard, on October 1, 1999. IIJ T1 Standard is a service package offering a high-quality, dedicated connection at 1.5Mbps with service level agreement (SLA) guarantees for Y167,000 a month. The service will first be offered in the Tokyo, Osaka, and Nagoya areas, with other areas to follow in the future. IIJ T1 Standard was developed to provide a full-time Internet connection at megabit-class speeds available to a greater number of users. By omitting some additional features and limiting the offered bandwidth to 1.5Mbps, IIJ has succeeded in providing users a new service package predicated on a different concept than that for traditional, full- featured dedicated access services. IIJ will continue to enhance its services going forward as it seeks to offer a greater variety of stable, high-speed Internet connection platforms to a greater number of users. Service Overview Initial fee Y50,000 Monthly fee Y167,000 SLA Average delay time within IIJ's domestic backbone is guaranteed Types of leased lines IIJ will make arrangements for NTT's Digital Access 1500, Digital Reach 1500, or similar services offered by other carriers. Troubleshooting Line is automatically monitored for 24-hours a day, 365 days a year. Restoration, however, is subject to the service operating hours of the line provider. IP addresses 1/32C (6 IP addresses). IP addresses will change when network operating center changes Routing Static routing only Net News Server capable of news feeds and news subscriptions not offered Comparison of fees and features Monthly fee SLA IIJ Y167,000 Yes AT&T Jens Y297,000 No PSI Net Y317,000 No Super OCN Y749,000 No UUNET Y272,100 No M2 COMMUNICATIONS DISCLAIMS ALL LIABILITY FOR INFORMATION PROVIDED WITHIN M2 PRESSWIRE. DATA SUPPLIED BY NAMED PARTY/PARTIES. -0- (C)1994-99 M2 COMMUNICATIONS LTD *** end of s